TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

American Journal of Oral Medicine and Radiology

Volume 11, Issue 1, 2024
Mcmed International
American Journal of Oral Medicine and Radiology
Issn
XXX-XXXX (Print), 2394 - 7721 (Online)
Frequency
bi-annual
Email
editorajomr@mcmed.us
Journal Home page
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
MYELODYSPLASIA SYNDROME CAUSED BY RADIOTHERAPY AND CHEMOTHERAPY
Author
Lakshmi1* and Harsha Vardhan P
Email
Lakshmi1@gmail.com
keyword
Antimetabolites, CT patients , Diabetes.
Abstract
Myelodysplastic Syndrome (MDS) is a varied group closely related to clonal hematopoietic disorder characterized by hypocellular or hypercellular bone with morphology deformed and mature, as well as peripheral blood cytopenia, followed by progressive paralysis of the myelodysplastic stem cell -proclivity to evolve into acute myeloid leukemia (AML). This study is to evaluate Myelodysplasia Syndrome Caused by Radiotherapy and Chemotherapy. The adjusted odds ratio for MDS risk in non-CT patients was 1.51-fold (95 percent confidence interval: 1.25–1.82) greater than the odds ratio in CT patients. A substantial relationship between higher MDS risk and diabetes, stroke, and ischemic heart disease was found in patients who also used alkylating drugs or topoisomerase II inhibitors. Hematological malignancies have been linked to those who have been exposed to ionising radiation by accident, as well as cancer patients who have had radiation therapy. Alkylating medicines, topoisomerase II inhibitors, and antimetabolites, on the other hand, are often mentioned in the literature as causes of CT-induced MDS. Radiation treatment and chemotherapy are both linked to the later development of MDS, according to this population-based nested case–control study. Following cancer therapy, some tumour sites are more prone to the formation of MDS than others. It is possible that RT and CT have a beneficial relationship
Download Broucher
Back to Top >>>>